Cargando…

Effect Size Analyses of Souvenaid in Patients with Alzheimer’s Disease

Background: Souvenaid(®) (uridine monophosphate, docosahexaenoic acid, eicosapentaenoic acid, choline, phospholipids, folic acid, vitamins B12, B6, C, and E, and selenium), was developed to support the formation and function of neuronal membranes. Objective: To determine effect sizes observed in cli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cummings, Jeffrey, Scheltens, Philip, McKeith, Ian, Blesa, Rafael, Harrison, John E., Bertolucci, Paulo H.F., Rockwood, Kenneth, Wilkinson, David, Wijker, Wouter, Bennett, David A., Shah, Raj C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5147481/ https://www.ncbi.nlm.nih.gov/pubmed/27767993 http://dx.doi.org/10.3233/JAD-160745

Ejemplares similares

Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer’s disease
por: Rijpma, Anne, et al.
Publicado: (2015)

Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2019)

The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer’s disease
por: Shah, Raj C, et al.
Publicado: (2013)

Souvenaid in the management of mild cognitive impairment: an expert consensus opinion
por: Cummings, Jeffrey, et al.
Publicado: (2019)

Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2016)

Economic evaluation of supplementing the diet with Souvenaid in patients with prodromal Alzheimer’s disease
por: Mar, Javier, et al.
Publicado: (2020)

Efficacy of Souvenaid(®) Combined with Acetylcholinesterase Inhibitors in the Treatment of Mild Alzheimer’s Disease
por: García-Alberca, José María, et al.
Publicado: (2023)

The Effect of Souvenaid on Functional Brain Network Organisation in Patients with Mild Alzheimer’s Disease: A Randomised Controlled Study
por: de Waal, Hanneke, et al.
Publicado: (2014)

Budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer’s Disease in Spain
por: Mar, Javier, et al.
Publicado: (2022)

The medical food Souvenaid affects brain phospholipid metabolism in mild Alzheimer’s disease: results from a randomized controlled trial
por: Rijpma, Anne, et al.
Publicado: (2017)

Assessment of a Potential Synergistic Effect of Souvenaid(®) in Mild Alzheimer’s Disease Patients on Treatment with Acetylcholinesterase Inhibitors: An Observational, Non-Interventional Study
por: Viñuela, Félix, et al.
Publicado: (2021)

Mild Cognitive Impairment with a High Risk of Progression to Alzheimer’s Disease Dementia (MCI-HR-AD): Effect of Souvenaid(®) Treatment on Cognition and (18)F-FDG PET Scans
por: Manzano Palomo, Maria Sagrario, et al.
Publicado: (2019)

The “rights” of precision drug development for Alzheimer’s disease
por: Cummings, Jeffrey, et al.
Publicado: (2019)

Alzheimer's disease: Unique markers for diagnosis & new treatment modalities
por: Aggarwal, Neelum T., et al.
Publicado: (2015)

Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer's dementia
por: de Oliveira, Fabricio Ferreira, et al.
Publicado: (2019)

Imaging in Alzheimer's disease
por: Scheltens, Philip
Publicado: (2009)

A prospective study of nutrition education and oral nutritional supplementation in patients with Alzheimer's disease
por: Pivi, Glaucia AK, et al.
Publicado: (2011)

10‐year frailty trajectory is associated with Alzheimer’s dementia after considering neuropathological burden
por: Wallace, Lindsay M. K., et al.
Publicado: (2021)

Con: Can biomarkers be gold standards in Alzheimer's disease?
por: Rockwood, Kenneth
Publicado: (2010)

Eres lo que comes : las recetas. 150 saludables y deliciosas recetas
por: McKeith, Gillian
Publicado: (2006)

Dementia with Lewy bodies
por: McKeith, Ian
Publicado: (2004)

Donald Eccleston, FRCPsych, PhD, DSc
por: McKeith, Ian
Publicado: (2018)

A Comparison Study of Quality Attributes of Ground Beef and Veal Patties and Thermal Inactivation of Escherichia coli O157:H7 after Double Pan-Broiling Under Dynamic Conditions
por: Li, KaWang, et al.
Publicado: (2017)

Grey matter atrophy in prodromal stage of dementia with Lewy bodies and Alzheimer’s disease
por: Blanc, Frederic, et al.
Publicado: (2016)

Metabolic Parameters as Predictors for Progression Free and Overall Survival of Patients with Metastatic Colorectal Cancer
por: Nemeth, Zsuzsanna, et al.
Publicado: (2020)

The Alzheimer’s disease drug development landscape
por: van Bokhoven, Pieter, et al.
Publicado: (2021)

The New Criteria for Alzheimer’s Disease - Implications for Geriatricians(*)
por: Molin, Pierre, et al.
Publicado: (2016)

Biomarkers to Measure Treatment Effects in Alzheimer's Disease: What Should We Look for?
por: Rockwood, Kenneth
Publicado: (2011)

Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy
por: Atri, Alireza, et al.
Publicado: (2013)

Comparison of cognitive decline between dementia with Lewy bodies and Alzheimer's disease: a cohort study
por: Walker, Zuzana, et al.
Publicado: (2012)

Integrative transcriptome analyses of the aging brain implicate altered splicing in Alzheimer’s disease susceptibility
por: Raj, Towfique, et al.
Publicado: (2018)

Open peer review commentary on building clinically relevant outcomes across the Alzheimer's disease spectrum
por: Rockwood, Kenneth
Publicado: (2021)

Heterogeneity of Alzheimer’s disease: consequence for drug trials?
por: Devi, Gayatri, et al.
Publicado: (2018)

A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
por: Jack, Clifford R., et al.
Publicado: (2016)

Alzheimer’s disease frequency peaks in the tenth decade and is lower afterwards
por: Farfel, Jose M., et al.
Publicado: (2019)

Les nouveaux critères de la Maladie d’Alzheimer – Perspective gériatrique(*)
por: Molin, Pierre, et al.
Publicado: (2016)

Intelectual demand and formal education as cognitive protection factors in Alzheimer’s disease
por: Wajman, José Roberto, et al.
Publicado: (2010)

Drug development in Alzheimer’s disease: the path to 2025
por: Cummings, Jeffrey, et al.
Publicado: (2016)

Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome
por: Dekker, Alain D., et al.
Publicado: (2017)

Differential Network Analyses of Alzheimer's Disease Identify Early Events in Alzheimer's Disease Pathology
por: Xia, Jing, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_rhj4g0esi5ebcc6kqd9nrkcln8